The Orai1-Drp1 axis mediates high glucose-induced mitochondrial fission and cardiomyocyte hypertrophy, presenting a potential therapeutic target for diabetic cardiomyopathy.
entry, via activation by p-ERK1/2-mediated phosphorylation at S616 or CnA-mediated dephosphorylation at S637 in DCM. Thus, the Orai1-Drp1 axis is a novel target for treating DCM.
Wu et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: